The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi

Clot-busting drugs save lives but carry real costs and bleeding risks. This wide-ranging review surveys an alternative: fibrinolytic enzymes drawn from nature — bacteria, fungi, fermented foods — and their bioengineered descendants.

The author catalogs enzymes from across the biological world that can dissolve fibrin, the protein scaffold of a clot, often more directly and with fewer side effects than first-generation agents like streptokinase and urokinase. Recombinant engineering, the review argues, has sharpened both their efficacy and safety, pointing toward cheaper, more precise thrombolytics.

The practical takeaway is that these enzymes — nattokinase among them — represent a potential lower-cost, safer class for clot-related disease. The status-quo friction is commercial: incumbent thrombolytics like alteplase have entrenched market positions.

We rate the evidence moderate: a sweeping 190-reference review, but a biotechnology survey rather than clinical-trial evidence, with most data preclinical or mechanistic. Its clinical significance is moderate and largely prospective — the promise of safer, cheaper clot dissolution is real, but it awaits the human trials that would move these agents from laboratory to bedside.